ETANA AND POI STRENGTHEN COLLABORATION TO DELIVER NEW HOPE FOR CANCER PATIENTS

Jakarta, February 1, 2026 — Cancer remains a major challenge to Indonesia’s national healthcare system, ranking as the third leading cause of death. According to data from the Global Cancer Observatory (Globocan) 2022, more than 408,661 new cases were recorded, with 242,099 deaths. Breast and cervical cancers account for the highest burden among women, while lung and colorectal cancers are most prevalent among men.

In response to this urgent situation, PT Etana Biotechnologies Indonesia (Etana), in commemoration of World Cancer Day (WCD) 2026 under the theme “United By Unique,” reaffirmed its commitment to building a comprehensive and sustainable cancer care ecosystem. Etana believes that overcoming cancer requires concrete action and strong cross-sector collaboration.

Randy Stevian, Director of Strategic Partnership & Business Development at Etana, emphasized that effective cancer management depends on seamless cooperation among stakeholders. “Continuous innovation is essential to ensure that cancer services—from early detection and optimal treatment to palliative care—are accessible, equitable, and of high quality for all communities,” he stated.

As part of its commitment to expanding access to innovative therapies, Etana has introduced a strategic portfolio of oncology biological products in Indonesia, including Bevagen® (Bevacizumab), the first locally produced Bevacizumab in the country; Etapidi® (Tislelizumab – Anti PD-1); Brukinsa® (Zanubrutinib – Anti BTK); and Hernera® (Neratinib Maleate – TKI). These therapies, which have previously been difficult to access, are now available at more affordable prices.

The availability of these products strengthens Etana’s position as a domestic biopharmaceutical manufacturer focused on delivering high-quality healthcare solutions. This initiative aligns with Etana’s vision to continuously develop affordable medicines, enabling broader and more sustainable access to advanced treatments.

“Our innovation in oncology is driven by the commitment to ensure that every patient in Indonesia regardless of their unique clinical condition—has access to high-quality, locally produced biotechnology therapies. Through safe, effective, and affordable solutions, we aim to provide new hope for cancer patients and improve their quality of life and future,” Randy added.

Etana also actively supports government initiatives in cancer prevention, diagnosis, and treatment. This commitment is particularly relevant in developing countries such as Indonesia, where challenges include limited healthcare access, regional disparities in medical facilities, and low public awareness of early detection.

As a concrete step, Etana has strengthened its strategic partnership with the Indonesian Oncology Association (Perhimpunan Onkologi Indonesia/POI), a professional organization that plays a leading role in cancer education and clinical management nationwide.

In line with its research-driven innovation strategy, Etana continues to develop precision oncology biotechnology solutions. The company believes that close collaboration with the medical community, especially clinicians affiliated with POI, will accelerate the adoption of the latest medical technologies in everyday clinical practice.

The Chairman of POI, Dr. dr. Cosphiadi Irawan, SpPD-KHOM, welcomed the initiative. “Cancer care is a multidisciplinary effort. Support from industry partners such as Etana is vital, particularly in facilitating strategic forums like this World Cancer Day Gathering and in expanding public education. This synergy is essential to strengthening patient-centered cancer care policies,” he said.

As part of the WCD 2026 program, POI and Etana organized the World Cancer Day Gathering and the Inauguration of the POI Central Board for the 2026–2029 term in Jakarta. The forum serves as a platform for stakeholders to discuss and formulate future directions for national cancer care policies.

In addition to formal activities, a digital campaign has been launched to encourage public participation. Through the hashtag #UnitedByUniquePOI, the public is invited to express their support for equitable and personalized access to cancer services. The campaign runs until February 19, 2026, as part of a collective effort to raise national awareness.

About Etana

Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility are able to produce biological therapy with halal certification from the Indonesian Ulama Council (MUI). Etana aspires to become the leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.

Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com